The 50 best-selling pharmaceuticals of 2022: COVID-19 vaccines poised to take a step back

[sizsus/Adobe Stock]

The COVID-19 pandemic has had a profound impact on the best-selling pharmaceuticals, leading to shifts in the list with Pfizer and BioNTech’s Comirnaty surpassing AbbVie’s Humira for the No. 1 spot in 2021. That momentum continued in 2022, with Pfizer and BioNTech jointly raking in $59.1 billion in revenue from the sales of the COVID-19 vaccine. Although Comirnaty maintained its position as the best-selling pharmaceutical of 2022, it experienced a roughly 5% drop in sales compared to the previous year.

As the best-selling pharmaceuticals of 2022 demonstrate, signs are emerging that the reign of COVID-19 vaccines and  other therapies appears to be slipping.. The two companies — and Moderna — plan on hiking prices to address the weakening demand.

Humira: The second best-selling pharmaceutical of 2022 looking strong

Meanwhile, the heavyweight tumor necrosis factor (TNF) block…

Read more
  • 0

Biktarvy shows high efficacy at five years in treatment-naïve adults with HIV

Gilead Sciences (NSDQ:GILD) announced that Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets) offered sustained efficacy at week 240 in two Phase studies (Study 1489 and Study 1490).

The Foster City, California–based company noted that there were no cases of treatment failure as a result of viral resistance detected in the studies.

The company presented the data at the 29th Conference on Retroviruses and Opportunistic Infections.

FDA approved Biktarvy in 2018, expanding its use in 2021 to include some HIV-positive children.

“Many people living with HIV are concerned about the ability of their therapy to achieve long-term viral suppression since they will likely be on treatment for the duration of their lives,” said Dr. David Alain Wohl, professor of medicine, division of infectious diseases at the University of North Carolina at Chapel Hill, in a statement.

Gilead Sciences recently agreed to pay a 3% royal…

Read more
  • 0

Gilead identifies counterfeit versions of two of its HIV drugs

Gilead Sciences (NSDQ: GILD) has announced that it has identified tampered and counterfeit versions of its HIV drugs Biktarvy and Descovy in the U.S. supply chain.

Biktarvy is a blockbuster drug cocktail, raking up $7.26 billion in sales last year. 2020 sales of Descovy were $478 million.

Foster City, Calif.–based Gilead said that unauthorized distributors have sold the drugs using genuine Gilead bottles but with a tampered counterfeit foil induction seal and drug.

The company is working to remove the counterfeit product from distribution.

“The safety of individuals taking Gilead medication is always our first priority,” said Dr. Merdad Parsey, chief medical officer and Gilead Sciences, in a statement. “We are taking aggressive action to ensure that healthcare providers and people who rely on our medicines can confidently distinguish authentic Gilead products from counterfeit drugs.”

The company also posted guidelines on its website to help…

Read more
  • 0